Ardelyx is trading at $3.41, up 6.23%, with its October 21 pre-market rise coinciding with broader biotech-sector strength.
- No clear company-specific announcement explains the rise; Ardelyx’s investor-relations page lists October 12 as its latest release, with no October 21 release shown.
- XBI was up 3.64% pre-market, pointing to sector momentum rather than a confirmed Ardelyx-specific catalyst.